Literature DB >> 13677481

On the detection of multiple-binding modes of ligands to proteins, from biological, structural, and modeling data.

Paul J Lewi1, Marc de Jonge, Frits Daeyaert, Luc Koymans, Maarten Vinkers, Jan Heeres, Paul A J Janssen, Eddy Arnold, Kalyan Das, Art D Clark, Stephen H Hughes, Paul L Boyer, Marie-Pierre de Béthune, Rudi Pauwels, Koen Andries, Mike Kukla, Donald Ludovici, Bart De Corte, Robert Kavash, Chih Ho, Paul J Lewis.   

Abstract

There are several indications that a given compound or a set of related compounds can bind in different modes to a specific binding site of a protein. This is especially evident from X-ray crystallographic structures of ligand-protein complexes. The availability of multiple binding modes of a ligand in a binding site may present an advantage in drug design when simultaneously optimizing several criteria. In the case of the design of anti-HIV compounds we observed that the more active compounds that are also resilient against mutation of the non-nucleoside binding site of HIV1-reverse transcriptase make use of more binding modes than the less active and resilient compounds.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 13677481     DOI: 10.1023/a:1025313705564

Source DB:  PubMed          Journal:  J Comput Aided Mol Des        ISSN: 0920-654X            Impact factor:   3.686


  12 in total

1.  Structure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors.

Authors:  J Ding; K Das; H Moereels; L Koymans; K Andries; P A Janssen; S H Hughes; E Arnold
Journal:  Nat Struct Biol       Date:  1995-05

2.  Structural analysis of a series of antiviral agents complexed with human rhinovirus 14.

Authors:  J Badger; I Minor; M J Kremer; M A Oliveira; T J Smith; J P Griffith; D M Guerin; S Krishnaswamy; M Luo; M G Rossmann
Journal:  Proc Natl Acad Sci U S A       Date:  1988-05       Impact factor: 11.205

3.  Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives.

Authors:  R Pauwels; K Andries; J Desmyter; D Schols; M J Kukla; H J Breslin; A Raeymaeckers; J Van Gelder; R Woestenborghs; J Heykants
Journal:  Nature       Date:  1990-02-01       Impact factor: 49.962

4.  A distinct binding mode of a hydroxyethylamine isostere inhibitor of HIV-1 protease.

Authors:  J Dohnálek ; J Hasek ; J Dusková ; H Petroková ; M Hradilek ; M Soucek ; J Konvalinka ; J Brynda ; J Sedlácek ; M Fábry
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2001-03

5.  Evolution of anti-HIV drug candidates. Part 1: From alpha-anilinophenylacetamide (alpha-APA) to imidoyl thiourea (ITU).

Authors:  D W Ludovici; M J Kukla; P G Grous; S Krishnan; K Andries; M P de Béthune; H Azijn; R Pauwels; E De Clercq; E Arnold; P A Janssen
Journal:  Bioorg Med Chem Lett       Date:  2001-09-03       Impact factor: 2.823

6.  Evolution of anti-HIV drug candidates. Part 3: Diarylpyrimidine (DAPY) analogues.

Authors:  D W Ludovici; B L De Corte; M J Kukla; H Ye; C Y Ho; M A Lichtenstein; R W Kavash; K Andries; M P de Béthune; H Azijn; R Pauwels; P J Lewi; J Heeres; L M Koymans; M R de Jonge; K J Van Aken; F F Daeyaert; K Das; E Arnold; P A Janssen
Journal:  Bioorg Med Chem Lett       Date:  2001-09-03       Impact factor: 2.823

7.  Evolution of anti-HIV drug candidates. Part 2: Diaryltriazine (DATA) analogues.

Authors:  D W Ludovici; R W Kavash; M J Kukla; C Y Ho; H Ye; B L De Corte; K Andries; M P de Béthune; H Azijn; R Pauwels; H E Moereels; J Heeres; L M Koymans; M R de Jonge; K J Van Aken; F F Daeyaert; P J Lewi; K Das; E Arnold; P A Janssen
Journal:  Bioorg Med Chem Lett       Date:  2001-09-03       Impact factor: 2.823

8.  Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant.

Authors:  K Das; J Ding; Y Hsiou; A D Clark; H Moereels; L Koymans; K Andries; R Pauwels; P A Janssen; P L Boyer; P Clark; R H Smith; M B Kroeger Smith; C J Michejda; S H Hughes; E Arnold
Journal:  J Mol Biol       Date:  1996-12-20       Impact factor: 5.469

9.  Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA.

Authors:  A Jacobo-Molina; J Ding; R G Nanni; A D Clark; X Lu; C Tantillo; R L Williams; G Kamer; A L Ferris; P Clark
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

10.  Crystal structures of metyrapone- and phenylimidazole-inhibited complexes of cytochrome P-450cam.

Authors:  T L Poulos; A J Howard
Journal:  Biochemistry       Date:  1987-12-15       Impact factor: 3.162

View more
  11 in total

1.  Molecular modelling prediction of ligand binding site flexibility.

Authors:  Ami Yi-Ching Yang; Per Källblad; Ricardo L Mancera
Journal:  J Comput Aided Mol Des       Date:  2004-04       Impact factor: 3.686

2.  Multiple ligand-binding modes in bacterial R67 dihydrofolate reductase.

Authors:  Hernán Alonso; Malcolm B Gillies; Peter L Cummins; Andrey A Bliznyuk; Jill E Gready
Journal:  J Comput Aided Mol Des       Date:  2005-03       Impact factor: 3.686

Review 3.  GPCR drug discovery: integrating solution NMR data with crystal and cryo-EM structures.

Authors:  Ichio Shimada; Takumi Ueda; Yutaka Kofuku; Matthew T Eddy; Kurt Wüthrich
Journal:  Nat Rev Drug Discov       Date:  2018-11-09       Impact factor: 84.694

4.  Binding of BIS like and other ligands with the GSK-3β kinase: a combined docking and MM-PBSA study.

Authors:  Nihar R Jena
Journal:  J Mol Model       Date:  2011-05-11       Impact factor: 1.810

5.  Rigorous treatment of multispecies multimode ligand-receptor interactions in 3D-QSAR: CoMFA analysis of thyroxine analogs binding to transthyretin.

Authors:  Senthil Natesan; Tiansheng Wang; Viera Lukacova; Vladimir Bartus; Akash Khandelwal; Stefan Balaz
Journal:  J Chem Inf Model       Date:  2011-04-08       Impact factor: 4.956

6.  "Reverse" carbocyclic fleximers: synthesis of a new class of adenosine deaminase inhibitors.

Authors:  Sarah C Zimmermann; Joshua M Sadler; Peter I O'Daniel; Nathaniel T Kim; Katherine L Seley-Radtke
Journal:  Nucleosides Nucleotides Nucleic Acids       Date:  2013       Impact factor: 1.381

7.  High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: strategic flexibility explains potency against resistance mutations.

Authors:  Kalyan Das; Joseph D Bauman; Arthur D Clark; Yulia V Frenkel; Paul J Lewi; Aaron J Shatkin; Stephen H Hughes; Eddy Arnold
Journal:  Proc Natl Acad Sci U S A       Date:  2008-01-29       Impact factor: 11.205

8.  Conformational landscape of the human immunodeficiency virus type 1 reverse transcriptase non-nucleoside inhibitor binding pocket: lessons for inhibitor design from a cluster analysis of many crystal structures.

Authors:  Kristina A Paris; Omar Haq; Anthony K Felts; Kalyan Das; Eddy Arnold; Ronald M Levy
Journal:  J Med Chem       Date:  2009-10-22       Impact factor: 7.446

9.  Molecular dynamics study of non-nucleoside reverse transcriptase inhibitor 4-[[4-[[4-[(E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile (TMC278/rilpivirine) aggregates: correlation between amphiphilic properties of the drug and oral bioavailability.

Authors:  Yulia Volovik Frenkel; Emilio Gallicchio; Kalyan Das; Ronald M Levy; Eddy Arnold
Journal:  J Med Chem       Date:  2009-10-08       Impact factor: 7.446

10.  Thiazolidinedione-based PI3Kα inhibitors: an analysis of biochemical and virtual screening methods.

Authors:  Jo-Anne Pinson; Oleg Schmidt-Kittler; Jiuxiang Zhu; Ian G Jennings; Kenneth W Kinzler; Bert Vogelstein; David K Chalmers; Philip E Thompson
Journal:  ChemMedChem       Date:  2011-01-04       Impact factor: 3.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.